Burnett J R, Wilcox L J, Telford D E, Kleinstiver S J, Barrett P H, Huff M W
The Departments of Medicine and Biochemistry and The John P. Robarts Research Institute, 4-16, University of Western Ontario, 100 Perth Drive, London, Ont. N6A 5K8, Canada.
Biochim Biophys Acta. 1998 Jul 31;1393(1):63-79. doi: 10.1016/s0005-2760(98)00059-9.
To further test the hypothesis that newly synthesized cholesteryl esters regulate hepatic apolipoprotein B (apoB) secretion into plasma, apoB kinetic studies were carried out in seven control miniature pigs and in seven animals after 21 days intravenous administration of the acyl coenzyme A:cholesterol acyltransferase (ACAT) inhibitor DuP 128 (2.2 mg/kg/day). Pigs were fed a fat (34% of calories; polyunsaturated/monounsaturated/saturated ratio, 1:1:1) and cholesterol (400 mg/day; 0.1%; 0.2 mg/kcal) containing pig chow based diet. DuP 128 significantly reduced total plasma triglyceride and very low density lipoprotein (VLDL) triglyceride concentrations by 36 and 31%, respectively (P<0.05). Autologous 131I-VLDL and 125I-LDL were injected simultaneously into each pig and apoB kinetic data was analyzed using multicompartmental analysis (SAAM II). The VLDL apoB pool size decreased by 26% (0.443 vs. 0.599 mg/kg; P<0. 001) which was due entirely to a 28% reduction in VLDL apoB production or secretion rate (1.831 vs. 2.548 mg/kg/h; P=0.006). The fractional catabolic rate (FCR) for VLDL apoB was unchanged. The LDL apoB pool size and production rate were unaffected by DuP 128 treatment. Hepatic microsomal ACAT activity decreased by 51% (0.44 vs. 0.90 nmol/min/mg; P<0.001). Although an increase in hepatic free cholesterol and subsequent decrease in both LDL receptor expression and LDL apoB FCR might be expected, this did not occur. The concentration of hepatic free cholesterol decreased 12% (P=0.008) and the LDL apoB FCR were unaffected by DuP 128 treatment. In addition, DuP 128 treatment did not alter the concentration of hepatic triglyceride or the activity of diacylglycerol acyltransferase, indicating a lack of effect of DuP 128 on hepatic triglyceride metabolism. In our previous studies, DuP 128 treatment of miniature pigs fed a low fat, cholesterol free diet, decreased VLDL apoB secretion by 65% resulting in a reduction in plasma apoB of 60%. We conclude that in miniature pigs fed a high fat, cholesterol containing diet, the inhibition of hepatic cholesteryl ester synthesis by DuP 128 decreases apoB secretion into plasma, but the effect is attenuated relative to a low fat, cholesterol free diet.
为了进一步验证新合成的胆固醇酯调节肝脏载脂蛋白B(apoB)分泌入血浆这一假说,我们对7只对照小型猪以及7只经静脉注射酰基辅酶A:胆固醇酰基转移酶(ACAT)抑制剂杜匹鲁卡胺(DuP 128,2.2毫克/千克/天)21天的动物进行了apoB动力学研究。给猪喂食一种含脂肪(占热量的34%;多不饱和/单不饱和/饱和比例为1:1:1)和胆固醇(400毫克/天;0.1%;0.2毫克/千卡)的猪饲料。DuP 128使血浆总甘油三酯和极低密度脂蛋白(VLDL)甘油三酯浓度分别显著降低了36%和31%(P<0.05)。将自体131I - VLDL和125I - LDL同时注射到每只猪体内,并使用多室分析(SAAM II)对apoB动力学数据进行分析。VLDL apoB池大小降低了26%(0.443对0.599毫克/千克;P<0.001),这完全是由于VLDL apoB产生或分泌速率降低了28%(1.831对2.548毫克/千克/小时;P = 0.006)。VLDL apoB的分解代谢率(FCR)未发生变化。LDL apoB池大小和产生速率不受DuP 128治疗的影响。肝脏微粒体ACAT活性降低了51%(0.44对0.90纳摩尔/分钟/毫克;P<0.001)。尽管预期肝脏游离胆固醇会增加,随后LDL受体表达和LDL apoB FCR会降低,但实际并未发生这种情况。肝脏游离胆固醇浓度降低了12%(P = 0.008),且LDL apoB FCR不受DuP 128治疗的影响。此外,DuP 128治疗并未改变肝脏甘油三酯浓度或二酰甘油酰基转移酶的活性,表明DuP 128对肝脏甘油三酯代谢没有影响。在我们之前的研究中,用DuP 128治疗喂食低脂、无胆固醇饮食的小型猪,可使VLDL apoB分泌减少65%,导致血浆apoB降低60%。我们得出结论,在喂食高脂肪、含胆固醇饮食的小型猪中,DuP 128抑制肝脏胆固醇酯合成可减少apoB分泌入血浆,但相对于低脂、无胆固醇饮食,这种作用减弱了。